---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000029"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:04:00.584670+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech announces EC approval of VYJUVEK for DEB; launch in Germany mid-2025

## Summary
- EC granted marketing authorization for VYJUVEK (beremagene geperpavec-svdt) to treat DEB from birth.
- Flexible dosing: at home or healthcare setting; patient/caregiver administration if appropriate.
- First corrective medicine for DEB in Europe; launch in Germany mid-2025; 1,000 DEB patients identified in France and Germany.

## SEC filing metadata
- accession: 0001711279-25-000029
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000029/0001711279-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000029/krys-20250428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000029
- JSON: https://secwatch.observer/filing/0001711279-25-000029.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.